Business Wire

CA-NEXTROLL

Share
AdRoll Group Rebrands as NextRoll, Launches Marketing Platform Services

AdRoll Group today announced it has rebranded as NextRoll, Inc. , a marketing and data technology company. Additionally, NextRoll is introducing external APIs to open its infrastructure, technology and data to a wide array of new companies. NextRoll is now comprised of three business units: RollWorks , an account-based platform for B2B marketing and sales teams; AdRoll , a growth marketing platform for direct-to-consumer (DTC) brands; and NextRoll Platform Services , a marketing-technology-as-a-service offering for brands, agencies, marketplaces, publishers, and marketing platforms to enhance current marketing capabilities or enable new revenue streams.

As online marketing has become more complex, many companies must choose between building their own technology stacks or working with closed-system providers, which can result in losing control, flexibility and customer insight. Now, with NextRoll Platform Services, companies can access leading marketing technology, data and channels without sacrificing relationships with their key audiences. For example, marketplaces can improve demand generation by giving their customers access to premium tools and audiences from NextRoll.

NextRoll Platform Services leverages rich data assets for unified, people-based profiles across first-, second- and third-party data, including more than 500 million identities and 1 billion devices. Additionally, NextRoll’s machine-learning capabilities enable companies to provide marketing messages, activate curated audiences and measure which efforts drive the greatest impact. NextRoll Platform Services customers can scale as needed, with a global infrastructure that covers 110 countries and manages up to five petabytes of stored data and 12 trillion real-time events processed daily.

“We’ve built an unrivaled marketing and data technology stack that enables marketers to better understand and engage with their audiences to make measurable decisions,” said Toby Gabriner, CEO of NextRoll. “With our new NextRoll Platform Services, we can offer these benefits to more companies, and allow them to innovate on top of our offerings. As we launch NextRoll Platform Services, it’s clear we’ve grown beyond our old name. Today, NextRoll is a marketing and data technology company.”

Services available today include:

Channels-as-a-Service

Channels-as-a-Service from NextRoll Platform Services allows businesses to expand their marketing solutions to new channels, including display ads, social media, native ads, email and video across devices enabling their customers to attract and re-engage audiences. With integrations to over 20 publishers and exchanges from Channels-as-a-Service, users can access the best inventory at any time to accelerate budget fulfillment and hit performance goals. They also gain granular insights into conversion, audience, performance and delivery data.

Audiences-as-a-Service

Many companies end up with vast amounts of raw audience data that is difficult to comprehend. With Audiences-as-a-Service from NextRoll Platform Services, companies have a unified and normalized view across identities and platforms within their existing data set, turning data into targetable segments they can ingest at scale and use in real-time. With this view, companies can better understand and serve each customer or segment. Companies can also enrich internal user profiles by leveraging the NextRoll database or package up these audience insights into premium, targetable segments for resale.

NextRoll Platform Services currently has 10 large customers that drive nearly $1 million in revenue per month, and has significant traction in the pipeline. A key contributor to the momentum is an existing joint venture with Rakuten in the Japanese market that leverages NextRoll Platform Services.

NextRoll Platform Services will release additional offerings in 2020 and beyond. Developers can access integration toolkits here .

About NextRoll

NextRoll, Inc. is a marketing and data technology company on a mission to accelerate growth for companies, big and small. Since 2007, our technology has powered a suite of data-driven marketing solutions and services. NextRoll Platform Services offer marketing-technology-as-a-service for brands, agencies, marketplaces, publishers and marketing platforms, to create more value for their business. Ambitious DTC brands use AdRoll products to make their display, social, and email advertising work together to accelerate business growth. RollWorks offers ambitious B2B companies an account-based platform to align their marketing and sales teams and confidently grow revenue. NextRoll empowers over 37,000 customers worldwide to understand, attract and engage buyers, driving growth for their businesses.

NextRoll is a privately-held company headquartered in San Francisco, CA. Company products honor the best practices for data use and privacy of leading associations including the Network Advertising Initiative (NAI) and the Digital Advertising Alliance’s (DAA) App Choices programs. Learn more about NextRoll at nextroll.com

AdRoll, NextRoll and RollWorks are trademarks NextRoll.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye